Our work in drug-resistant TB
The Union advocates for increased research and development, and conducts clinical trials to reduce treatment time and improve outcomes for patients in countries with the highest burdens of disease.
The Union also provides practical and experience-based support to countries implementing care for people with DR-TB. Our expertise is based on our extensive research with partners supporting the nine-month regimen, including partnering on the first randomised control trial into a new regimen for multidrug-resistant TB (TREAT TB).
With the new World Health Organization guidelines focusing on shorter, all oral, regimens for MDR-TB, The Union continues to support countries to implement the latest evidence-based treatments.
Read more about TREAT TB (Technology, Research, Education and Technical Assistance for Tuberculosis), an ambitious initiative that was launched by The Union, seeking to contribute new knowledge regarding shorter, more tolerable treatment regimens for MDR-TB.
The Union used an operational research approach to test a shortened treatment regimen for multidrug-resistant TB. The study first demonstrated a greater than 80% success rate in Bangladesh, Cameroon and Niger and The Union continued to work to develop and implement shorter more effective regimens for the treatment of MDR-TB.
DR-TB Union news
National survey on the impact of the war in Ukraine on TB diagnostics and treatment services in 2022
A Letter in a forthcoming issue of the IJTLD highlights the impact of the war in Ukraine on TB services. The preprint is free to read.
As part of the Contribute to the Elimination of Tuberculosis in Africa (CETA) Project, a clinical internship programme was organised for…
An Editorial in the IJTLD explains the increase in the Journal's impact factor and describes how we are improving the Journal for authors and readers. The preprint is free to read.
Correspondence in a forthcoming issue of IJTLD examines the impact of the war in Ukraine on healthcare systems in the area, including both Eastern and non-Eastern European countries and future management of TBI and TB disease. The preprint is free to read.